

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jinxin Fertility Group Limited**

**錦欣生殖醫療集團有限公司\***

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock Code: 1951)**

**PROFIT WARNING  
AND  
APPOINTMENT OF ACTING CHIEF FINANCIAL OFFICER**

This announcement is made by Jinxin Fertility Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders (the “**Shareholders**”) and potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with International Financial Reporting Standards) for the six months ended June 30, 2025 (“**1H 2025**”) and the information currently available to the Board, it is expected that the Group will record a loss of not more than RMB1,090 million for 1H 2025, as compared to the net profit of the Group of approximately RMB190 million for the six months ended June 30, 2024 (“**1H 2024**”). This loss was primarily attributable to impairment and provisions recognized in respect of certain goodwill, intangible assets and other financial assets of the Group, in connection with its business in the United States and Laos. In determining the need and extent for such impairment and provisions, the Company has carefully evaluated the Group’s operating and financial performance as well as future prospects of its businesses. The actual amount of impairment and provisions remain subject to further assessment by the Company.

The Company believes that the impairment and provisions for 1H 2025 would not have a material adverse impact on the Group's overall business operations and cash flow, as they constitute predominately one-off non-cash items. While the macroeconomic and industry conditions in 1H 2025 posed challenges to the Group's businesses, the Company remains highly confident in the long-term prospects of the industry and the Group's growth, as underpinned by the Group's solid industry foundation, continuous support from favorable national policies on the industry, as well as the Group's ongoing efforts to enhance clinical treatment results, patient care and service offerings.

The Company is still in the process of finalizing the interim results of the Group for 1H 2025. The information contained in this announcement is only based on the preliminary assessment of the unaudited consolidated management accounts of the Group for 1H 2025, which are subject to finalization and other potential adjustments, if any, and have not been reviewed or confirmed by the auditors of the Group or the audit and risk management committee of the Board. Shareholders and potential investors of the Company should refer to the interim results announcement of the Group for 1H 2025, which is expected to be published by the end of August 2025.

## **APPOINTMENT OF ACTING CHIEF FINANCIAL OFFICER**

The Board is pleased to announce that it has resolved to appoint, with effect from the date of this announcement, Mr. DONG Yang (“**Mr. Dong**”), an executive Director and the chief executive officer of the Company, as the acting chief financial officer of the Company. Mr. Dong will be responsible for overseeing the financial management, business development and operations of the Group as well as other relevant duties assigned by the Group.

Mr. Dong Yang (董陽), aged 39, is the chief executive officer of the Company and has been an executive Director of the Company since June 29, 2020. Recently, since July 1, 2025, Mr. Dong has returned to his full duties in China and Hong Kong following his assignment in the United States. He was appointed as non-executive Director and co-chief executive officer of the Company on May 3, 2018 and June 29, 2020, respectively, and was subsequently re-designated as the chief executive officer on March 28, 2021. From 2017 to 2020, he was the chief financial officer of certain members of the Company's sister group. Prior to that, Mr. Dong had served with PricewaterhouseCoopers and an asset management firm collectively for eight years. Mr. Dong has obtained his master's degree in business administration from the School of Management of Massachusetts Institute of Technology and the Hong Kong University of Science and Technology, and is a certified public accountant with the Chinese Institute of Certified Public Accountants.

As of the date of this announcement, Mr. Dong is deemed to be interested in 10,097,818 shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), including 3,419,318 underlying shares of the Company granted to him under the share schemes of the Company. Save as disclosed herein, there is no other matter relating to the appointment of Mr. Dong as acting chief financial officer of the Company that needs to be brought to the attention of the shareholders of the Company and there is no other information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board extends a warm welcome to Mr. Dong on his new position as the acting chief financial officer of the Company.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Jinxin Fertility Group Limited**  
**Dong Yang**  
*Chief Executive Officer, Acting Chief Financial Officer  
and Executive Director*

Hong Kong, August 8, 2025

*As at the date of this announcement, the board of directors of the Company comprises Dr. John G. Wilcox, Mr. Dong Yang, Ms. Lyu Rong and Dr. Geng Lihong, as executive directors; Mr. Zhong Yong, as Chairman and non-executive director, and Mr. Fang Min, Ms. Hu Zhe and Ms. Yan Xiaoqing, as non-executive directors; and Dr. Chong Yat Keung, Mr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive directors.*

\* *For identification purposes only*